CN108601738A - 固体可溶性焦磷酸铁制剂、药盒和其使用方法 - Google Patents

固体可溶性焦磷酸铁制剂、药盒和其使用方法 Download PDF

Info

Publication number
CN108601738A
CN108601738A CN201680064674.5A CN201680064674A CN108601738A CN 108601738 A CN108601738 A CN 108601738A CN 201680064674 A CN201680064674 A CN 201680064674A CN 108601738 A CN108601738 A CN 108601738A
Authority
CN
China
Prior art keywords
solid particulate
weight
iron
dialysate
pyrophosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680064674.5A
Other languages
English (en)
Chinese (zh)
Inventor
R.基安尼
A.古普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockwell Medical Inc
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of CN108601738A publication Critical patent/CN108601738A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1666—Apparatus for preparing dialysates by dissolving solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
CN201680064674.5A 2015-09-04 2016-09-02 固体可溶性焦磷酸铁制剂、药盒和其使用方法 Pending CN108601738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214908P 2015-09-04 2015-09-04
US62/214908 2015-09-04
PCT/US2016/050120 WO2017040937A1 (en) 2015-09-04 2016-09-02 Solid soluble ferric pyrophosphate formulations, kits, and methods using the same

Publications (1)

Publication Number Publication Date
CN108601738A true CN108601738A (zh) 2018-09-28

Family

ID=56926337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680064674.5A Pending CN108601738A (zh) 2015-09-04 2016-09-02 固体可溶性焦磷酸铁制剂、药盒和其使用方法

Country Status (18)

Country Link
US (1) US11517555B2 (enExample)
EP (1) EP3344235A1 (enExample)
JP (1) JP7055738B2 (enExample)
KR (1) KR20180050346A (enExample)
CN (1) CN108601738A (enExample)
AU (1) AU2016315877B2 (enExample)
BR (1) BR112018004244A2 (enExample)
CA (1) CA2997328A1 (enExample)
CL (1) CL2018000566A1 (enExample)
CO (1) CO2018002421A2 (enExample)
EA (1) EA201890642A1 (enExample)
IL (1) IL257796B (enExample)
MX (1) MX2018002633A (enExample)
PE (1) PE20181162A1 (enExample)
PH (1) PH12018500463A1 (enExample)
SG (1) SG10202107245UA (enExample)
UA (1) UA124923C2 (enExample)
WO (1) WO2017040937A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
FR3109734B1 (fr) * 2020-05-04 2025-04-11 Univ Claude Bernard Lyon Système de dialyse pour le traitement du sepsis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
JP5038552B2 (ja) * 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
JP3778240B2 (ja) * 1998-06-22 2006-05-24 ライオン株式会社 不快な味がマスキングされた造粒組成物及びその製造方法
CA2344548C (en) * 1998-09-18 2007-03-13 Rockwell Medical Technologies, Inc. Method and apparatus for preparing liquid dialysate
ES2469642T3 (es) * 2000-04-20 2014-06-18 Jagotec Ag Procedimiento mejorado para partículas de fármaco insoluble en agua
JP2002302435A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 多孔性物質およびその製造法
US20040052854A1 (en) 2000-12-26 2004-03-18 Tomohiro Yoshinari Porous substances and methods for producing the same
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ATE522151T1 (de) * 2005-07-15 2011-09-15 Unilever Nv Eisen verstärktes lebensmittel und zusatzstoff
CN107007624A (zh) * 2013-02-01 2017-08-04 查拉克有限责任公司 用可溶性焦磷酸铁治疗铁缺乏症的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RITA WEGMULLER等: "Particle Size Reduction and Encapsulation Affect the Bioavailability of Ferric Pyrophosphate in Rats", 《NUTRIENT METABOLISM》 *
刘淑兰 编: "《生物药剂学与药物动力学》", 30 September 1984 *
张汝华主编: "《工业药剂学》", 31 July 2001, 中国医药科技出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物

Also Published As

Publication number Publication date
AU2016315877B2 (en) 2022-05-26
CO2018002421A2 (es) 2018-07-19
JP7055738B2 (ja) 2022-04-18
EP3344235A1 (en) 2018-07-11
SG10202107245UA (en) 2021-08-30
AU2016315877A1 (en) 2018-04-05
BR112018004244A2 (pt) 2018-09-25
US20180243256A1 (en) 2018-08-30
EA201890642A1 (ru) 2018-10-31
IL257796A (en) 2018-04-30
MX2018002633A (es) 2019-02-07
KR20180050346A (ko) 2018-05-14
IL257796B (en) 2021-09-30
UA124923C2 (uk) 2021-12-15
PE20181162A1 (es) 2018-07-19
JP2018529674A (ja) 2018-10-11
CA2997328A1 (en) 2017-03-09
US11517555B2 (en) 2022-12-06
CL2018000566A1 (es) 2018-08-03
WO2017040937A1 (en) 2017-03-09
PH12018500463A1 (en) 2018-09-17

Similar Documents

Publication Publication Date Title
EP2016940B1 (en) Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
TWI583378B (zh) 透析酸前驅物組成物、其用途、以及提供透析酸濃縮物溶液之方法
JP2001513370A (ja) 水溶性ビタミン及び栄養素を含む透析溶液
JP2011144199A (ja) 透析のための緩衝組成物
TW201219040A (en) Dialysis precursor composition
US11517555B2 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
EP2934483B1 (en) Dialysis composition
Zhou et al. The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study
US7857977B2 (en) Packaging of ferric pyrophosphate for dialysis
US20200155453A1 (en) Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses
CN103340827B (zh) 蔗糖铁注射液及其制法
CN109550053B (zh) 一种双药配位聚合物抗结核纳米药物的制备方法
HK1261642A1 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
CN121127251A (zh) 以含3价铈的铈化合物作为有效成分的药物组合物
JPH0338527A (ja) 血液透析用製剤およびその製造方法
CN109475519B (zh) 含氨基酸的hd酸浓缩物
CA2638081C (en) Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
JP6925148B2 (ja) 鉄含有輸液剤
TW201841645A (zh) 血液透析用a劑
CA2986095A1 (en) Liquid pharmaceutical formulations of tetraiodothyronine
HK1159489A (en) Buffered compositions for dialysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261642

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180928

RJ01 Rejection of invention patent application after publication